Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data

Parnetti, Lucilla, Amenta, Francesco, Gallai, Virgilio · 2001 · Mechanisms of Ageing and Development

Abstract

This paper has reviewed the documentation on the clinical efficacy of choline alphoscerate, a cholinergic precursor, considered as a centrally acting parasympathomimetic drug in dementia disorders and in acute cerebrovascular disease. Thirteen published clinical trials, examining in total 4054 patients, have evaluated the use of choline alphoscerate in various forms of dementia disorders of degenerative, vascular or combined origin, such as senile dementia of the Alzheimer's type (SDAT) or vascular dementia (VaD) and in acute cerebrovascular diseases, such as transitory ischemic attack (TIA) and stroke. Analysis has assessed the design of each study, in particular with respect to experimental design, number of cases, duration of treatment and tests used to evaluate drug clinical efficacy. Most of the ten studies performed in dementia disorders were controlled trials versus a reference drug or placebo. Overall, 1570 patients were assessed in these studies, 854 of which in controlled trials. As detected by validated and appropriate tests, such as Mini Mental State Evaluation (MMSE) in SDAT and Sandoz Clinical Assessment Geriatric (SCAG) in VaD, administration of choline alphoscerate significantly improved patient clinical condition. Clinical results obtained with choline alphoscerate were superior or equivalent to those observed in control groups under active treatment and superior to the results observed in placebo groups. Analysis stresses the clear internal consistency of clinical data gathered by different experimental situations on the drug effect, especially with regard to the cognitive symptoms (memory, attention) characterising the clinical picture of adult-onset dementia disorders. The therapeutic usefulness of choline alphoscerate in relieving cognitive symptoms of chronic cerebral deterioration differentiates this drug from cholinergic precursors used in the past, such as choline and lecithin. Three uncontrolled trials were performed with choline alphoscerate in acute cerebrovascular stroke and TIA, totalling 2484 patients. The results of these trials suggest that this drug might favour functional recovery of patients with cerebral stroke and should be confirmed in future investigations aimed at establish the efficacy of the drug in achieving functional recovery of patients with acute cerebrovascular disease.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0047-6374(01)00312-8

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 44 references

Research works printed but not linked: 11

  1. Ban, 1991, Choline alphoscerate in elderly patients with cognitive decline due to dementing illness, New Trends Clin. Neuropharmacol., 5, 1
  2. Canonico, 1990, Effetti neurochimici e comportamentali di α-GFC (colina alfoscerato), Basi. Raz. Ter., 20, 53
  3. Drago, 1990, Effetti comportamentali di α-GFC in modelli di invecchiamento cerebrale patologico, Basi. Raz. Ter., 20, 65
  4. Govoni, 1990, Effetti di αGFC sul comportamento di evitamento passivo del ratto e sui livelli di acetilcolina, Basi. Raz. Ter., 20, 55
  5. Paciaroni, 1993, Studio clinico di efficacia e tollerabilità di α-GFC (colina alfoscerato), controllato vs oxiracetam in pazienti affetti da declino cognitivo di grado lieve-moderato su base vascolare, Giorn. It. Ric. Clin. Ter., 14, 29
  6. Palleschi, 1992, Valutazione di efficacia e tollerabilità di α-GFC (colina alfoscerato) in pazienti affetti da declino cognitivo di grado lieve-moderato, Geriatria, 4, 61
  7. Reynolds J.E.F. (Eds.), 1996. Parasimpathomimetics. In: Martindale—The Extra Pharmacopoeia, thirty-first ed. Royal Pharmaceutical Society, London, pp. 1413–1428.
  8. Schettini, 1990, Effetto del trattamento in vivo con α-GFC (colina alfoscerato) sull'attività dei sistemi di trasduzione a livello cerebrale, Basi. Raz. Ter., 20, 23
  9. Schettini, 1993, Effetto della colina alfoscerato in pazienti anziani affetti da demenza degenerativa primaria, Basi. Raz. Ter., 23, 108
  10. Tomasina, 1991, Studio clinico dell'efficacia terapeutica e della tollerabilità della colina alfoscerato in 15 soggetti con compromissione delle funzioni cognitive successiva ad ischemia cerebrale focale acuta, Riv. Neuropsichiatria Sci. Affini., 37, 21
  11. Vezzetti, 1992, Valutazione clinica e strumentale dell‘effetto della colina alfoscerato sul decadimento cerebrale, Presse Med. It., 5, 141

Cited by

See all 132

Metadata

Authors
Parnetti, L., Amenta, F., & Gallai, V.
Affiliations
  • University of Perugia (IT)
  • Università di Camerino (IT)
Corresponding author
Parnetti, Lucilla
Venue
Mechanisms of Ageing and Development
Publisher
Elsevier BV
Published
2001-11
Volume
122
Issue
16
Pages
2041-2055
ISSN
0047-6374 (ISSN-L)
OpenAlex
W2145884031
Cited by
132
References
44
Citations by year
2026: 2 · 2025: 6 · 2024: 16 · 2023: 8 · 2022: 15 · 2021: 8 · 2020: 7 · 2019: 7 · 2018: 2 · 2017: 7 · 2016: 5 · 2015: 6 · 2014: 6 · 2013: 4 · 2012: 7
FWCI
1.21
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Mechanisms of Ageing and Development (publishedVersion)
  • PubMed (publishedVersion)
  • Unicam Scientific Publications (University of Camerino) (submittedVersion)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
choline alphoscerate, cognitive decline, dementia, Alzheimer's disease, vascular dementia, stroke, transient ischemic attack, acute cerebrovascular disease, clinical efficacy, functional recovery, attention and memory
MeSH terms
Cerebrovascular Disorders, Clinical Trials as Topic, Cognition Disorders, Glycerylphosphorylcholine, Humans, Parasympathomimetics, Periodicals as Topic, Statistics as Topic, Dementia, Vascular

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. https://app.cochat.ai/papers/10.1016/s0047-6374(01)00312-8
The paper
Parnetti, L., Amenta, F., & Gallai, V. (2001). Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mechanisms of Ageing and Development. https://doi.org/10.1016/s0047-6374(01)00312-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.